Atea Pharmaceuticals, Inc. (AVIR)
$
3.05
+0.02 (0.66%)
Key metrics
Financial statements
Free cash flow per share
-1.3954
Market cap
238.3 Million
Price to sales ratio
572.8125
Debt to equity
0.0034
Current ratio
19.1662
Income quality
0.8585
Average inventory
0
ROE
-0.3255
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of antiviral therapeutics for patients battling viral infections. The company's stock is identified with the symbol 'AVIR' in the market. Its lead product candidate, AT-527, is currently in Phase II clinical trials for the treatment of COVID-19. Additionally, Atea is developing several other products, including AT-752, an oral purine nucleoside prodrug that has completed Phase Ia clinical trials for dengue; AT-777, an NS5A inhibitor; and AT-787, a co-formulated, oral, pan-genotypic fixed-dose combination of AT-527 and AT-777 aimed at treating hepatitis C virus (HCV). The company also offers AT-281, a pharmaceutically acceptable salt designed for the treatment or prevention of RNA viral infections such as dengue fever, yellow fever, Zika virus, and coronaviridae infections. Furthermore, Ruzasvir, an investigational oral, pan-genotypic NS5A inhibitor for chronic HCV infection, is also in its portfolio. The company reported selling, general, and administrative expenses of $48,849,000.00 indicating its operational overhead costs. Atea recorded an operating income of -$192,950,000.00 reflecting its earnings from core operations and an income before tax ratio of 0.00 which demonstrates the pre-tax margin. The net income ratio is 0.00 showcasing the company's profitability margin. The stock is affordable at $2.88 suitable for budget-conscious investors. With a market capitalization of $238,290,016.00 the company is classified as a small-cap player and is considered a key entity in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, the stock has a low average trading volume of 379,468.00 indicating lower market activity. Atea Pharmaceuticals belongs to the Healthcare sector, driving innovation and growth in the biopharmaceutical field while actively pursuing the advancement of therapies for viral infections.
Is Atea Pharmaceuticals, Inc. (AVIR) a good investment?
Investing in Atea Pharmaceuticals, Inc. (AVIR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Atea Pharmaceuticals, Inc. (AVIR)'s stock forecast?
Analysts predict Atea Pharmaceuticals, Inc. stock to fluctuate between $2.46 (low) and $4.02 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Atea Pharmaceuticals, Inc.'s market capitalization?
As of 2025-11-26, Atea Pharmaceuticals, Inc.'s market cap is $238,290,016, based on 78,127,874 outstanding shares.
How does Atea Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Atea Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Atea Pharmaceuticals, Inc. (AVIR) stock?
To buy Atea Pharmaceuticals, Inc. (AVIR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AVIR. Place an order (Market, Limit, etc.).
What is the best time to invest in Atea Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Atea Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2 | Growth: 22.70%.
Where can I find Atea Pharmaceuticals, Inc.'s investor relations reports?
Visit https://ateapharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Atea Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Atea Pharmaceuticals, Inc. stock?
All-time high: $46.91 (2021-10-04) | All-time low: $2.46 (2025-05-15).
What are the key trends affecting Atea Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Atea Pharmaceuticals, Inc. ( AVIR ) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Company Participants Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Conference Call Participants Jordan Feld Anthony Martinez Nancy Reau Eric Lawitz Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Good morning, and welcome to the Atea Pharmaceuticals Virtual KOL event.
seekingalpha.com
Atea Pharmaceuticals, Inc. ( AVIR ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - CFO, Executive VP of Legal & Secretary Conference Call Participants Selina Zhou Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2025 Financial Results and Business Update Conference Call.
seekingalpha.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - CFO, Executive VP of Legal & Secretary Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Great. Hello, everyone.
seekingalpha.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrea J. Corcoran - CFO, Executive VP of Legal & Secretary Janet M.
globenewswire.com
States Change in Board Composition Sorely Needed Expresses Support for Radoff-JEC Group Nominees STAMFORD, Texas, March 31, 2025 (GLOBE NEWSWIRE) -- Driver Management Company LLC (“Driver”) today delivered a letter to Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) withdrawing a notice of nomination delivered to the Company on March 19, 2025 in order not to compete against the highly qualified candidates nominated for election to the Company's board of directors (the “Board”) by Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”).
globenewswire.com
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement:
seekingalpha.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Chief Executive Officer & Founder Janet Hammond - Chief Development Officer Arantxa Horga - Chief Medical Officer Andrea Corcoran - Chief Financial Officer & Executive Vice President, Legal Conference Call Participants Bella Camaj - JPMorgan Andy Hsieh - William Blair Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
See all news
